Corporation highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic acid, EPA, on ...

Amarin Corporation announced the presentation of new in vitro data on eicosapentaenoic acid (EPA) at the American College of Cardiology's Annual Scientific Session & Expo from March 29-31, 2025.

Corporation announced that additional in vitro mechanistic data with eicosapentaenoic acid, EPA, will be presented at the ...

“At Amarin, we continue to invest in the science behind VASCEPA/VAZKEPA to further explore the potential mechanistic activities of EPA, administered clinically in the form of our icosapent ethyl ...

NEWARK, Del, March 14, 2025 (GLOBE NEWSWIRE) -- The global Omega-3 market is poised for remarkable expansion, projected to surge from USD 5,785.1 million in 2025 to USD 13,323.1 million by 2035 ...

Amarin Corporation plc (NASDAQ:AMRN) Q4 2024 Earnings Call Transcript March 12, 2025 Amarin Corporation plc beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.06.

Total Revenue: $228.6 million for 2024. Cash Position: $294 million with no debt at year-end 2024. Fourth Quarter Revenue: $62.3 million, including $60.1 million in net product revenue and $2.2 ...

Introduction: Icosapent ethyl (IPE) is indicated for the treatment of severe hypertriglyceridemia (triglycerides ≥500 mg/dl) and for reducing the risk of cardiovascular (CV) events in statin-treated ...

-- Company Reports Fourth Quarter 2024 Total Revenues of $62.3 Million, Operating Expenses of $43.0 Million and Year End 2024 Cash Position of $294.2 Million -- In addition, Aaron Berg commented ...

DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today announced financial results for the fourth quarter of 2024 and provided a review of ...